Bora Pharmaceuticals Co., LTD.

6472

TW0006472004

Pharmaceuticals

End-of-day quote Taiwan S.E. Other stock markets 06:00:00 2024-05-01 pm EDT			5-day change	1st Jan Change
752 ^TWD	-1.70%		-0.53%	+17.68%

Apr. 12	Bora Pharmaceuticals Co., LTD. agreed to acquire remaining 34.3% stake in Bora Biologics Co., Ltd.	CI
Apr. 01	Bora Pharmaceuticals Co., LTD. completed the acquisition of Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd..	CI

Bora Biologics Co., Ltd. announced that it has received TWD 1.10362 billion in funding from Bora Pharmaceuticals Co., LTD.

June 13, 2022

Bora Biologics Co., Ltd. announced that it has completed a private placement of 39,415,000 units at a price of TWD 28 per unit to returning investor Bora Pharmaceuticals Co., LTD. for gross proceeds of TWD 1,103,620,000 on June 14, 2022.

Latest news about Bora Pharmaceuticals Co., LTD.

Bora Pharmaceuticals Co., LTD. agreed to acquire remaining 34.3% stake in Bora Biologics Co., Ltd.	Apr. 11	CI
Bora Pharmaceuticals Co., LTD. completed the acquisition of Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd..	Mar. 31	CI
Bora Pharmaceuticals USA Inc. announced that it expects to receive $1 billion in funding from Bora Pharmaceuticals Co., LTD.	Mar. 28	CI
Bora Pharmaceuticals Co., LTD. announces an Equity Buyback for 1,000,000 shares, representing 0.99% for TWD 6,832.17 million.	Mar. 07	CI
Bora Pharmaceuticals Co., LTD. Announces Cash Dividend for Second Half of 2023	Mar. 07	CI
Bora Pharmaceuticals Co., LTD. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Bora Pharmaceuticals Co., LTD. authorizes a Buyback Plan.	Mar. 06	CI
Bora Pharmaceuticals USA Inc. announced that it expects to receive $100 million in funding from Bora Pharmaceuticals Co., LTD.	Mar. 06	CI
Bora Pharmaceuticals Co., LTD.(TWSE:6472) added to Taiwan TAIEX Index	Jan. 22	CI
Bora Pharmaceuticals Co., LTD. agreed to acquire Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd. for approximately $210 million.	Jan. 15	CI
Bora Pharmaceuticals Co., LTD. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
SunWay Biotech Co., LTD. agreed to acquire Bora Health Inc from Bora Pharmaceuticals Co., LTD..	23-08-20	CI
Bora Pharmaceuticals Co., LTD. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Bora Pharmaceuticals Co., Ltd. Elects Lin Hsin-I as Independent Director	23-06-05	CI
Bora Pharmaceuticals Co., Ltd. Announces Cash Dividend, Payable on July 28, 2023	23-06-05	CI
Bora Pharmaceuticals Co., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Bora Pharmaceuticals Co., LTD. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
Bora Pharmaceuticals Co., LTD. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Bora Pharmaceuticals Co., LTD. Announces Contract Signing of the Syndicated Loan with Syndicate Bank	22-09-21	CI
Bora Pharmaceuticals Co., LTD. completed the acquisition of TWi Pharmaceuticals, Inc.	22-08-31	CI
Bora Pharmaceuticals Co., LTD. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Bora Pharmaceuticals Co., LTD. Announces Common Stock Cash Dividend, Payable on August 2, 2022	22-06-22	CI
Bora Pharmaceuticals Co., LTD. announced that it has received TWD 800 million in funding	22-06-13	CI
Bora Pharmaceuticals Co., LTD. agreed to acquire TWi Pharmaceuticals, Inc.	22-06-13	CI
Bora Biologics Co., Ltd. announced that it has received TWD 1.10362 billion in funding from Bora Pharmaceuticals Co., LTD.	22-06-13	CI

Chart Bora Pharmaceuticals Co., LTD.

Duration

Period

More charts

Company Profile

Bora Pharmaceuticals Co Ltd is a Taiwan-based company principally engaged in the agency and sales of western medicines, as well as the research, development, manufacture and sales of new drugs and health products. The Company's main products are categorized into prescription drugs and health care products, including central nervous drugs, cardiovascular drugs, antibiotics, antiviral agents, ophthalmic drugs, gastrointestinal drugs, foam ingots and health care products. In addition, the Company has biopharmaceutical technologies related to the development of cell lines for the production of protein drugs, the development and analysis of upstream and downstream processes, as well as the establishment of quality control and testing specifications and the creation of cell banks.

Sector

Pharmaceuticals

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Bora Pharmaceuticals Co., LTD.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

752 TWD

Average target price

865 TWD

Spread / Average Target

+15.03%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BORA PHARMACEUTICALS CO., LTD.	+17.68%	2.35B
ELI LILLY AND COMPANY	+26.07%	681B
NOVO NORDISK A/S	+21.43%	556B
JOHNSON & JOHNSON	-5.53%	361B
MERCK & CO., INC.	+16.75%	325B
ABBVIE INC.	+4.51%	285B
ASTRAZENECA PLC	+13.55%	235B
NOVARTIS AG	+3.66%	199B
ROCHE HOLDING AG	-11.57%	189B
PFIZER, INC.	-4.15%	157B

Other Pharmaceuticals

Bora Pharmaceuticals Co., LTD.

Equities

6472

TW0006472004

Pharmaceuticals

Bora Biologics Co., Ltd. announced that it has received TWD 1.10362 billion in funding from Bora Pharmaceuticals Co., LTD.

EPS Revisions